Drug development for orphan diseases in the context of personalized medicine

Translational Research

Volumn 154, Issue 6, 2009, Pages 314-322

  Brewer, George J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; IMIGLUCERASE; PENICILLAMINE; RECOMBINANT ERYTHROPOIETIN; ROFECOXIB; TETRATHIOMOLYBDIC ACID; TRIENTINE; ZINC; ZINC ACETATE;

ABSENCE OF SIDE EFFECTS; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; FUNDING; GAUCHER DISEASE; HEALTH PROGRAM; HUMAN; LAW; LEUKOPENIA; MEDICINE; MICROCYTOSIS; OFF LABEL DRUG USE; ORPHAN DISEASE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; RARE DISEASE; REVIEW; SICKLE CELL ANEMIA; SIDE EFFECT; UNITED STATES; WILSON DISEASE;

EID: 70449507812     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.03.008     Document Type: Review

References (40)

1. NIH Office of Rare Diseases (ORD). About us. Available at: http://rarediseases.info.nih.gov/aboutus.aspx. Accessed January 27, 2009.
2. Orphan drugs and orphan diseases: clinical realities and public policy. Proceedings of a conference held in Ann Arbor, MI, September 27-29, 1982. New York: A.R. Liss, 1983.
3. National Organization for Rare Disorders. About NORD. Available at: http://www.rarediseases.org/info/about.html. Accessed January 27, 2009.
4. U.S. Food and Drug Administration. Office of Orphan Products Development. Available at: http://www.fda.gov/orphan/. Accessed January 27, 2009.
5. Haffner M.E., Torrent-Farnell J., and Maher P.D. Does orphan drug legislation really answer the needs of patients?. Lancet 371 (2008) 2041-2044
6. Brewer G.J. Wilson's disease: a clinician's guide to recognition, diagnosis, and management (2001), Kluwer Academic Publishers, Boston, MA
7. Brewer G.J. Wilson's disease. In: Fauci A.S., Braunward E., and Kasper D.L. (Eds). Harrison's principles of internal medicine. 17 ed (2008), McGraw-Hill Companies, New York 2449-2452
8. Scheinberg I.H., and Sternlieb I. Wilson's disease. In: Smith L.H.J. (Ed). Major problems in internal medicine (1984), W.B. Saunders Company, Philadelphia, PA 1-171
9. Schilsky M.L. Wilson disease: genetic basis of copper toxicity and natural history. Semin Liver Dis 16 (1996) 83-95
10. Brewer G.J., Schoomaker E.B., Leichtman D.A., Kruckleberg W.C., Brewer L.F., and Myers N. The uses of pharmacologic doses of zinc in the treatment of sickle cell anemia. In: Brewer G.J., and Prasad A.S. (Eds). Zinc metabolism: current aspects in health and disease (1977), Allan R. Liss, New York 241-258
11. Oelshlegel F.J., and Brewer G.J. Absorption of pharmacologic doses of zinc. In: Brewer G.J., and Prasad A.S. (Eds). Zinc metabolism: current aspects in health and disease (1977), Alan R. Liss, New York 299-316
12. Prasad A.S., Brewer G.J., Schoomaker E.B., and Rabbini P. Hypocupremia induced by zinc therapy in adults. JAMA 240 (1978) 2166-2168
13. Brewer G.J., Hill G.M., Prasad A.S., Cossack Z.T., and Rabbani P. Oral zinc therapy for Wilson's disease. Ann Intern Med 99 (1983) 314-319
14. Hill G.M., Brewer G.J., Prasad A.S., Hydrick C.R., and Hartmann D.E. Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens. Hepatology 7 (1987) 522-528
15. Brewer G.J., Yuzbasiyan-Gurkan V., and Dick R. Zinc therapy of Wilson's disease: VIII. Dose response studies. J Trace Elem Exp Med 3 (1990) 227-234
16. Brewer G.J., Yuzbasiyan-Gurkan V., Johnson V., Dick R.D., and Wang Y. Treatment of Wilson's disease with zinc XII: Dose regimen requirements. Am J Med Sci 305 (1993) 199-202
17. Brewer G.J., Yuzbasiyan-Gurkan V., Johnson V., Dick R.D., and Wang Y. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents. J Am Coll Nutr 12 (1993) 26-30
18. Yuzbasiyan-Gurkan V., Brewer G.J., Abrams G.D., Main B., and Giacherio D. Treatment of Wilson's disease with zinc. V. Changes in serum levels of lipase, amylase, and alkaline phosphatase in patients with Wilson's disease. J Lab Clin Med 114 (1989) 520-526
19. Brewer G.J., Yuzbasiyan-Gurkan V., and Johnson V. Treatment of Wilson's disease with zinc. IX: response of serum lipids. J Lab Clin Med 118 (1991) 466-470
20. Brewer G.J., Johnson V., and Kaplan J. Treatment of Wilson's disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function. J Lab Clin Med 129 (1997) 649-652
21. Brewer G.J., Hill G., Prasad A., and Dick R. The treatment of Wilson's disease with zinc. IV. Efficacy monitoring using urine and plasma copper. Proc Soc Exp Biol Med 184 (1987) 446-455
22. Yuzbasiyan-Gurkan V., Grider A., Nostrant T., Cousins R.J., and Brewer G.J. Treatment of Wilson's disease with zinc: X. intestinal metallothionein induction. J Lab Clin Med 120 (1992) 380-386
23. Brewer G.J., Johnson V.D., Dick R.D., Fink J.K., Kluin K.J., and Hedera P. Treatment of Wilson's disease with zinc XVII: treatment during pregnancy. Hepatology 31 (2000) 364-370
24. Brewer G.J., Dick R.D., Johnson V.D., Fink J.K., Kluin K.J., and Daniels S. Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years. J Lab Clin Med 137 (2001) 191-198
25. Brewer G.J., Terry C.A., Aisen A.M., and Hill G.M. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol 44 (1987) 490-493
26. Gooneratne S.R., Howell J.M., and Gawthorne J.M. An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep. Br J Nutr 46 (1981) 469-480
27. Bremner I., Mills C.F., and Young B.W. Copper metabolism in rats given di- or trithiomolybdates. J Inorg Biochem 16 (1982) 109-119
28. Mills C.F., El-Gallad T.T., and Bremner I. Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats. J Inorg Biochem 14 (1981) 189-207
29. Mills C.F., El-Gallad T.T., Bremner I., and Weham G. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem 14 (1981) 163-175
30. Brewer G.J., Dick R.D., Yuzbasiyan-Gurkan V., Tankanow R., Young A.B., and Kluin K.J. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 48 (1991) 42-47
31. Brewer G.J., Hedera P., Kluin K.J., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 60 (2003) 379-385
32. Brewer G.J., Askari F., Lorincz M.T., et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 63 (2006) 521-527
33. Brewer GJ, Askari F, Dick R, et al. The treatment of Wilson's disease with tetrathiomolybdate (TM): V. Control of free copper by TM and a comparison with trientine. Transl Res. In press.
34. Brewer G.J., Dick R.D., Grover D.K., et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 6 (2000) 1-10
35. Gartner E.M., Griffith K.A., Pan Q., et al. A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs 2 (2009) 159-165
36. Henry N.L., Dunn R., Merjaver S., et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone refractory prostate cancer. Oncology 71 (2006) 168-175
37. Redman B.G., Esper P., Pan Q., et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 9 (2003) 1666-1672
38. Pass H.I., Brewer G.J., Dick R., Carbone M., and Merajver S. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann Thorac Surg 86 (2008) 383-389
39. Vine A.K., and Brewer G.J. Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Trans Am Ophthalmol Soc 100 (2002) 73-76
40. Brewer G.J. Fundamental problems lie ahead in the drug discovery and commercialization process: restructuring of the pharmaceutical industry and an improved partnership with academia are required. J Investig Med 54 (2006) 291-302